Inventor · disambiguated record
Andrew Baik
Also filed as: BAIK ANDREW
4 granted patents·13 pending applications·29 citations·filing 2016–2025
69Inventor score
Files withREGENERON PHARMA17
Top patents by PatentIndex Score
17 records- 0195US11208458B2Compositions and methods for internalizing enzymesREGENERON PHARMA·Filed 2018·Granted Dec 28, 2021·28 cites·20 claims
- 0280US2025171520A1Compositions and methods for internalizing enzymesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0374US12215138B2Compositions and methods for internalizing enzymesREGENERON PHARMA·Filed 2021·Granted Feb 4, 2025·0 cites·24 claims
- 0468US12258597B2Methods and compositions for therapeutic protein deliveryREGENERON PHARMA·Filed 2019·Granted Mar 25, 2025·1 cites·23 claims
- 0566US2023338477A1Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe diseaseREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0665US12252544B2Anti-CD63 antibodies, conjugates, and uses thereofREGENERON PHARMA·Filed 2019·Granted Mar 18, 2025·0 cites·24 claims
- 0764US2025032642A1Crispr-mediated transgene insertion in neonatal cellsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0863US2025382377A1Anti-cd63 antibodies, conjugates, and uses thereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 0963US2025188433A1Compositions and methods for internalizing enzymesREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1058US2025041455A1Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe diseaseREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1156US2023149563A1Compositions and methods for expressing factor ix for hemophilia b therapyREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1252US2025197829A1Methods and compositions for therapeutic protein deliveryREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1348US2025276092A1Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody responseREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1447US2025242018A1Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administrationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1546US2025277048A1The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administrationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1645US2025242056A1Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosingREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1743US2019112588A1Compositions and methods for internalizing enzymesREGENERON PHARMA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Andrew Baik files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →